Mathews Adera

发表

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

D. Lockhart, J. Flanagan, C. Barlow, 2015, PloS one.

Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia

R. Dammerman, Sonnie Kim, Mathews Adera, 2018, Clinical pharmacology in drug development.

A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

R. Dammerman, Sonnie Kim, Mathews Adera, 2017, Psychopharmacology bulletin.

A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

R. Dammerman, Sonnie Kim, Mathews Adera, 2017, Psychopharmacology bulletin.

Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers

P. Mudd, F. Johnson, A. Bragat, 2013, Clinical pharmacology in drug development.

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study

Kelli C. Dominick, E. Berry-Kravis, P. Ventola, 2021, Frontiers in Pharmacology.

Development of an adapted Clinical Global Impression scale for use in Angelman syndrome

A. Kolevzon, P. Ventola, G. Heimer, 2021, Journal of neurodevelopmental disorders.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

R. Recker, M. McClung, A. Kriegman, 2007, Bone.

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations

P. Boudes, Mathews Adera, C. Overton, 2011 .

Pharmacokinetics and muscle distribution of AT2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers

S. Sitaraman, A. Bragat, P. Boudes, 2011 .

A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT

P. Boudes, Mathews Adera, A. Gladden, 2011 .

PRELIMINARY LONG-TERM SAFETY, TOLERABILITY, AND ASSESSMENTS OF RENAL FUNCTION OF ADULT FABRY PATIENTS RECEIVING TREATMENT WITH AT1001 (MIGALASTAT HYDROCHLORIDE), A PHARMACOLOGICAL CHAPERONE, FOR UP TO 3 YEARS

D. Hughes, A. Bragat, J. Castelli, 2010 .